Basel Medical Group Ltd is a US-listed company in the health care facilities industry. Its financial year ends in June.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$10
Revenue-to-maturity cash-flow model
Base case. Range ~$7.4–$14 across our lower- and higher-growth cases (25%–35% a year).
Price vs value
No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.
Basel Medical Group Ltd valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds1 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Basel Medical Group Ltd's trailing-twelve-month revenue grew 49.9% year on year, with a free-cash-flow margin of -5.4%. Where it stands out: change in share count of -91.6% ranks 1 of 13 health care facilities companies we cover. Where it lags: stock pay as % of revenue of 1.8% ranks 12 of 12 health care facilities companies we cover.
Current signal Revenue growth accelerating: TTM revenue growth rose to 49.9% (+35.2pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Fast growth. Revenue grew 49.9% over the last 12 months, against a median of 14.0% for health care facilities companies we cover.
- Growth speeding up. The growth rate is 35.2 points higher than a quarter earlier.
- Shrinking share count. Diluted shares fell 91.6% in a year, so each share owns more of the business.
Things to watch
- Burning cash. Free cash flow was -5.4% of revenue over the last 12 months.
- Below peers: stock pay as % of revenue. Stock pay as % of revenue of 1.8% ranks 12 of 12 health care facilities companies we cover (median 0.6%).
- Below peers: days sales outstanding. Days sales outstanding of 228 days ranks 12 of 12 health care facilities companies we cover (median 48 days).
Price chart
- 1 day+1.4%
- 1 week+12.3%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $12.8M
- Net margin
- -4.5%
- EPS (TTM, diluted)
- $-0.37
Growth
- Revenue growth
- +49.9%
- Change in growth rate
- +35.2 pts
- Share count change
- −91.6%
Cash
- Free cash flow (TTM)
- -$688,281
- FCF margin
- -5.4%
- Stock pay % of revenue
- 1.8%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for BMGL from the sources we follow. See filings →
Valuation models
We value Basel Medical Group Ltd as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.79 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | ~$10 ~$7.4–$14 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.8 ~$6.1–$15 | Left out: out of range vs price (0.16x) |
| Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$10 ~$7.4–$14 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Basel Medical Group Ltd with Health Care Facilities in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Basel Medical Group Ltd: too few analysts cover it.
Positioning
- Short interest
- 0.2% of tradable shares
- Days to cover
- 0.05 at average volume
- Short interest, 1 month
- −92% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 6.3% of shares
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Basel Medical Group Ltd in five measures
Fundamentals
Financial statements
| Fiscal year | 2024 Jun 2024 | 2025 Jun 2025 | 2026 Jun 2026 |
|---|---|---|---|
| Income | |||
| Revenue | 7 | 9 | 13 |
| Net income | 2 | −8 | −1 |
| Diluted EPS | $0.10 | −$0.43 | −$0.61 |
| Growth (year on year) | |||
| Revenue | — | +14.6% | +49.9% |
| Net income | — | −622.3% | — |
| Diluted EPS | — | −546.3% | — |
| Margins | |||
| Net margin | 20.6% | −94.0% | −4.5% |
| Free-cash-flow margin | 24.9% | −40.6% | −5.4% |
| Cash flow | |||
| Cash from operations | 2 | −3 | −0 |
| Capital spending | 0 | 0 | 0 |
| Free cash flow | 2 | −3 | −1 |
| Stock-based pay | — | — | 0 |
| Free cash flow after stock pay | — | — | −1 |
| Balance sheet | |||
| Cash | 1 | 2 | 0 |
| Total debt | 3 | 4 | 7 |
| Net debt (negative = net cash) | 2 | 2 | 6 |
| Diluted shares | 16m | 19m | 2m |
Financial health
- Short-term assets cover short-term liabilities $9m of assets due within a year against $8m of liabilities due within a year.
- Short-term assets cover long-term liabilities $9m short-term assets against $3m of longer-dated liabilities.
- More cash than debt $409,464 of cash against $7m of debt.
- Debt below 40% of shareholders' equity Debt is 191% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$494,885 of operating cash flow against $7m of debt.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- −91.6%
- year over year
- Days sales outstanding
- 228 days
- receivables vs revenue
Competitors: side by side with peers
| Last 12 months unless stated | BMGL | NIVF | CCM | SNDA | NHC | CON | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $13m | $24m | $64m | $526m | $1.6bn | $2.3bn | $3.1bn |
| Revenue growth, last 12 months | 49.9% | 336.3% | 20.1% | 49.4% | 6.9% | 14.0% | 14.0% |
| Revenue growth, 3-year average | — | — | −11.2% | 29.0% | 12.8% | — | 8.1% |
| Revenue growth, latest quarter | — | — | — | 122.0% | 8.8% | 10.0% | 8.6% |
| Gross margin | — | 4.0% | 5.6% | — | — | — | 21.2% |
| Operating margin | — | −45.2% | −56.8% | −3.3% | 9.3% | 16.4% | 9.0% |
| Operating margin, 3-year average | — | — | −71.7% | 0.0% | 7.8% | 15.9% | 7.9% |
| Net margin | −4.5% | 41.7% | −20.2% | −23.3% | 9.0% | 8.7% | 4.8% |
| Cash from operations / revenue | −3.9% | −46.1% | −43.8% | −3.0% | 12.1% | 14.7% | 7.7% |
| Free-cash-flow margin | −5.4% | −46.7% | −56.1% | −10.0% | 9.4% | 11.7% | 4.7% |
| Free-cash-flow margin, 3-year average | — | — | −70.4% | −6.9% | 8.4% | 10.2% | 5.9% |
| Stock pay / revenue | 1.8% | −50.9% | 0.0% | 1.4% | 0.3% | 0.6% | 0.6% |
| Change in share count | −91.6% | >999% | 0.0% | 57.5% | 0.9% | 1.6% | 0.9% |
Peer comparison
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 49.9% | 14.0% | 2 of 13 |
| Change in growth rate Growth | +35.2pp | -1.4pp | 3 of 13 |
| Net margin Profitability | -4.5% | 4.8% | 10 of 13 |
| Free-cash-flow margin Cash generation | -5.4% | 4.7% | 10 of 13 |
| Stock pay as % of revenue Cash generation | 1.8% | 0.6% | 12 of 12 |
| Long-term debt as % of assets Balance sheet | 19.1% | 37.7% | 5 of 13 |
| Change in share count Balance sheet | -91.6% | 0.9% | 1 of 13 |
| Days sales outstanding Balance sheet | 228 days | 48 days | 12 of 12 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
Who owns it
Funds buying and selling- Reported value
- $3,440
- Institutions reporting
- 1
- Positions opened / closed
- 1 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| UBS Group AG | $3,440 | 0K | 100.0% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Basel Medical Group Ltd's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Basel Medical Group Ltd in brief
- What does Basel Medical Group Ltd do?
- Basel Medical Group Ltd is a US-listed company in the health care facilities industry. Its financial year ends in June.
- What is Basel Medical Group Ltd's stock ticker?
- Basel Medical Group Ltd trades under the ticker BMGL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is Basel Medical Group Ltd's revenue, and how fast is it growing?
- Over its most recent trailing twelve months, Basel Medical Group Ltd reported revenue of $12.8M, 49.9% higher than a year earlier, according to its SEC filings.
- What is Basel Medical Group Ltd's free cash flow?
- Basel Medical Group Ltd's free-cash-flow margin is -5.4% of revenue over the trailing twelve months, ranking 10 of the 13 health care facilities companies we cover.
- How much debt does Basel Medical Group Ltd have?
- Basel Medical Group Ltd's debt-to-equity ratio is 190.8%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
- Who are Basel Medical Group Ltd's competitors?
- In our Health Care Facilities peer group, the companies closest to Basel Medical Group Ltd are Newgenivf Group Ltd, Concord Medical Services Holdings Ltd, Sonida Senior Living, Inc., National Healthcare Corp and Concentra Group Holdings Parent, Inc. The side-by-side comparison below sets their revenue, margins and growth against Basel Medical Group Ltd's.
Follow research on Basel Medical Group Ltd
New research on the companies we cover arrives in the weekly email. Free, one email a week.